A novel steroidal antiandrogen targeting wild type and mutant androgen receptors

Biochemical Pharmacology

Volumn 82, Issue 11, 2011, Pages 1651-1662

  Andrieu, Thomas ^a   Bertolini, Reto ^a   Nichols, Sara E ^b   Setoud, Raschid ^a   Frey, Felix J ^a   Baker, Michael E ^c   Frey, Brigitte M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

22Rv1; Androgen receptor; Anti androgen; LNCaP; Prostate cancer; Steroidal antiandrogen

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE DERIVATIVE; ANTIANDROGEN; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; RB 274; RB 346; RB 348; RB 350; RB 352; RB 355; RB 364; RB 365; RB 374; RB 42; RB 43; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGEN ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CARBAMATES; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; DIHYDROTESTOSTERONE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUTAMIDE; HUMANS; MALE; MODELS, MOLECULAR; MUTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTIONAL ACTIVATION;

EID: 80255123457     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.08.020     Document Type: Article

References (58)

1. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate CA Cancer J Clin 22 4 1972 232 240
2. D.A. Loblaw, K.S. Virgo, R. Nam, M.R. Somerfield, E. Ben-Josef, and D.S. Mendelson Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 12 2007 1596 1605 (Pubitemid 46733088)
3. D. Raudrant, and T. Rabe Progestogens with antiandrogenic properties Drugs 63 5 2003 463 492 (Pubitemid 36337727)
4. S. Rybikowski, C. Maurin, J. Deturmeny, V. Delaporte, E. Lechevallier, and C. Coulange PSA and spironolactone Prog Urol 20 2 2010 154 157
5. N. Craft, Y. Shostak, M. Carey, and C.L. Sawyers A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat Med 5 3 1999 280 285 (Pubitemid 29124362)
6. D. Gioeli, S.B. Ficarro, J.J. Kwiek, D. Aaronson, M. Hancock, and A.D. Catling Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites J Biol Chem 277 32 2002 29304 29314
7. N.A. Colabufo, V. Pagliarulo, F. Berardi, M. Contino, C. Inglese, and M. Niso Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins Eur J Pharmacol 601 1-3 2008 38 42
8. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, and R. Vessella Molecular determinants of resistance to antiandrogen therapy Nat Med 10 1 2004 33 39 (Pubitemid 38524696)
9. T. Hara, J. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki, and M. Kusaka Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res 63 1 2003 149 153 (Pubitemid 36070433)
10. M.E. Taplin, B. Rajeshkumar, S. Halabi, C.P. Werner, B.A. Woda, and J. Picus Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663 J Clin Oncol 21 14 2003 2673 2678 (Pubitemid 46606310)
11. T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, and Y. Shimizu Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient Cancer Res 65 21 2005 9611 9616 (Pubitemid 41541433)
12. J.P. Gaddipati, D.G. McLeod, H.B. Heidenberg, I.A. Sesterhenn, M.J. Finger, and J.W. Moul Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers Cancer Res 54 11 1994 2861 2864 (Pubitemid 24187763)
13. H. Suzuki, N. Sato, Y. Watabe, M. Masai, S. Seino, and J. Shimazaki Androgen receptor gene mutations in human prostate cancer J Steroid Biochem Mol Biol 46 6 1993 759 765 (Pubitemid 24045142)
14. M. Watanabe, T. Ushijima, T. Shiraishi, R. Yatani, J. Shimazaki, and T. Kotake Genetic alterations of androgen receptor gene in Japanese human prostate cancer Jpn J Clin Oncol 27 6 1997 389 393
15. J.S. Horoszewicz, S.S. Leong, E. Kawinski, J.P. Karr, H. Rosenthal, and T.M. Chu LNCaP model of human prostatic carcinoma Cancer Res 43 4 1983 1809 1818 (Pubitemid 13122588)
16. J. Veldscholte, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, C. Berrevoets, and E. Claassen A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Commun 173 2 1990 534 540
17. A. van Bokhoven, M. Varella-Garcia, C. Korch, W.U. Johannes, E.E. Smith, and H.L. Miller Molecular characterization of human prostate carcinoma cell lines Prostate 57 3 2003 205 225 (Pubitemid 37267805)
18. J. Tan, Y. Sharief, K.G. Hamil, C.W. Gregory, D.Y. Zang, and M. Sar Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells Mol Endocrinol 11 4 1997 450 459 (Pubitemid 27147013)
19. R.M. Sramkoski, T.G. Pretlow II, J.M. Giaconia, T.P. Pretlow, S. Schwartz, and M.S. Sy A new human prostate carcinoma cell line, 22Rv1 In Vitro Cell Dev Biol Anim 35 7 1999 403 409 (Pubitemid 29380004)
20. C.G. Tepper, D.L. Boucher, P.E. Ryan, A.H. Ma, L. Xia, and L.F. Lee Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line Cancer Res 62 22 2002 6606 6614 (Pubitemid 35364127)
21. G.N. Brooke, M.G. Parker, and C.L. Bevan Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression Oncogene 27 21 2008 2941 2950 (Pubitemid 351668003)
22. J. Veldscholte, C.A. Berrevoets, and E. Mulder Studies on the human prostatic cancer cell line LNCaP J Steroid Biochem Mol Biol 49 4-6 1994 341 346 (Pubitemid 24240620)
23. K. Steketee, L. Timmerman, A.C. Ziel-van der Made, P. Doesburg, A.O. Brinkmann, and J. Trapman Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer Int J Cancer 100 3 2002 309 317 (Pubitemid 34728989)
24. X.B. Shi, A.H. Ma, L. Xia, H.J. Kung, and R.W. de Vere White Functional analysis of 44 mutant androgen receptors from human prostate cancer Cancer Res 62 5 2002 1496 1502 (Pubitemid 34407813)
25. X.Y. Zhao, P.J. Malloy, A.V. Krishnan, S. Swami, N.M. Navone, and D.M. Peehl Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 6 2000 703 706 (Pubitemid 30398797)
26. D.J. van de Wijngaart, M. Molier, S.J. Lusher, R. Hersmus, G. Jenster, and J. Trapman Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H J Biol Chem 285 7 2010 5097 5105
27. M. Urushibara, J. Ishioka, N. Hyochi, K. Kihara, S. Hara, and P. Singh Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors Prostate 67 8 2007 799 807 (Pubitemid 46828934)
28. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, and V. Arora Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 5928 2009 787 790
29. A. Liu, K.E. Carlson, and J.A. Katzenellenbogen Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography J Med Chem 35 11 1992 2113 2129
30. L. McRobb, D.J. Handelsman, R. Kazlauskas, S. Wilkinson, M.D. McLeod, and A.K. Heather Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay J Steroid Biochem Mol Biol 110 1-2 2008 39 47
31. O. Adeyemo, P.J. Kallio, J.J. Palvimo, K. Kontula, and O.A. Janne A single-base substitution in exon 6 of the androgen receptor gene causing complete androgen insensitivity: the mutated receptor fails to transactivate but binds to DNA in vitro Hum Mol Genet 2 11 1993 1809 1812 (Pubitemid 23326604)
32. W. Sherman, T. Day, M.P. Jacobson, R.A. Friesner, and R. Farid Novel procedure for modeling ligand/receptor induced fit effects J Med Chem 49 2 2006 534 553 (Pubitemid 43157487)
33. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, and D.T. Mainz Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J Med Chem 47 7 2004 1739 1749 (Pubitemid 38380917)
34. K. Zhu, M. Shirts, and R. Friesner Improved methods for side chain and loop predictions via the protein local optimization program: variable dielectric model for implicitly improving the treatment of polarization effects J Chem Theory Comput 210 2007 8 19
35. C.E. Bohl, Z. Wu, D.D. Miller, C.E. Bell, and J.T. Dalton Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design J Biol Chem 282 18 2007 13648 13655 (Pubitemid 47100516)
36. J.S. Sack, K.F. Kish, C. Wang, R.M. Attar, S.E. Kiefer, and Y. An Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone Proc Natl Acad Sci USA 98 9 2001 4904 4909 (Pubitemid 32397055)
37. V.D. Handratta, T.S. Vasaitis, V.C. Njar, L.K. Gediya, R. Kataria, and P. Chopra Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model J Med Chem 48 8 2005 2972 2984 (Pubitemid 40552912)
38. X.Y. Zhao, B. Boyle, A.V. Krishnan, N.M. Navone, D.M. Peehl, and D. Feldman Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a J Urol 162 6 1999 2192 2199
39. P. Masiakowski, R. Breathnach, J. Bloch, F. Gannon, A. Krust, and P. Chambon Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line Nucleic Acids Res 10 24 1982 7895 7903
40. S. Kansra, S. Yamagata, L. Sneade, L. Foster, and N. Ben-Jonathan Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release Mol Cell Endocrinol 239 1-2 2005 27 36 (Pubitemid 40848726)
41. M.O. Joly-Pharaboz, M.C. Soave, B. Nicolas, F. Mebarki, M. Renaud, and O. Foury Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP J Steroid Biochem Mol Biol 55 1 1995 67 76
42. B.J. Attardi, J. Burgenson, S.A. Hild, and J.R. Reel Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells Mol Cell Endocrinol 222 1-2 2004 121 132 (Pubitemid 38906659)
43. A. Tomura, K. Goto, H. Morinaga, M. Nomura, T. Okabe, and T. Yanase The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein J Biol Chem 276 30 2001 28395 28401
44. L. Cantin, F. Faucher, J.F. Couture, K.P. de Jesus-Tran, P. Legrand, and L.C. Ciobanu Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12 J Biol Chem 282 42 2007 30910 30919 (Pubitemid 350035181)
45. V.V. Sumbayev, J.K. Jensen, J.A. Hansen, and P.A. Andreasen Novel modes of oestrogen receptor agonism and antagonism by hydroxylated and chlorinated biphenyls, revealed by conformation-specific peptide recognition patterns Mol Cell Endocrinol 287 1-2 2008 30 39
46. A. Shiau, D. Barstad, J. Radek, M. Meyers, K. Nettles, and B. Katzenellenbogen Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism Nat Struct Biol 35 2002 9 64
47. I. Segard-Maurel, K. Rajkowski, N. Jibard, G. Schweizer-Groyer, E.E. Baulieu, and F. Cadepond Glucocorticosteroid receptor dimerization investigated by analysis of receptor binding to glucocorticosteroid responsive elements using a monomer-dimer equilibrium model Biochemistry 35 5 1996 1634 1642
48. P. Farla, R. Hersmus, J. Trapman, and A.B. Houtsmuller Antiandrogens prevent stable DNA-binding of the androgen receptor J Cell Sci 118 Pt 18 2005 4187 4198 (Pubitemid 41488956)
49. Z. Kang, O.A. Janne, and J.J. Palvimo Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor Mol Endocrinol 18 11 2004 2633 2648 (Pubitemid 39482054)
50. F.H. Schroder Cyproterone acetate - mechanism of action and clinical effectiveness in prostate cancer treatment Cancer 72 12 Suppl. 1993 3810 3815 (Pubitemid 23361533)
51. P.C. Sogani, M.R. Vagaiwala, and W.F. Whitmore Jr. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy Cancer 54 4 1984 744 750 (Pubitemid 14060360)
52. F. Lund, and F. Rasmussen Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study Br J Urol 61 2 1988 140 142 (Pubitemid 18067142)
53. R. Migliari, G. Muscas, and E. Usai Effect of Casodex on sleep-related erections in patients with advanced prostate cancer J Urol 148 2 Pt 1 1992 338 341
54. M.A. Fousteris, U. Schubert, D. Roell, J. Roediger, N. Bailis, and S.S. Nikolaropoulos 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth Bioorg Med Chem 18 19 2010 6960 6969
55. E.T. Keller, W.B. Ershler, and C. Chang The androgen receptor: a mediator of diverse responses Front Biosci 1 1996 d59 d71
56. C.S. Higano Side effects of androgen deprivation therapy: monitoring and minimizing toxicity Urology 61 2 Suppl. 1 2003 32 38 (Pubitemid 36349540)
57. Y. Niu, T.M. Chang, S. Yeh, W.L. Ma, Y.Z. Wang, and C. Chang Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails Oncogene 29 25 2010 3593 3604
58. J. Hodoniczky, C.G. Sims, W.M. Best, J.M. Bentel, and J.A. Wilce The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides Biopolymers 90 5 2008 595 603